Tirzepatide and Blood Pressure: 32 Trials, Two Signals

A meta-analysis that appeared in Endocrine on 15 August 2026 pulled together 32 randomised controlled trials, 47,332 participants in total, and asked a very specific question: when people take tirzepatide or semaglutide, what happens to blood pressure related adverse events. The headline result, as the authors present it, is that the two drugs do not behave the same, and the divergence isn’t one-sided, it cuts both ways.

Blood pressure has sat in the background of this drug class for a while, usually treated as a welcome knock-on effect of weight loss. Here, that broad story is split into two separate tracks, one reassuring and one cautionary, and the authors only see that split clearly with tirzepatide.

One note before getting into the figures: everything described below relates to approved medicines studied in patients. Peptra Labs provides these compounds as reference material for laboratory research only, and nothing here should be read as advice for human use.

What the analysis combined

The team searched PubMed, Scopus, Web of Science, Embase, CENTRAL, and ClinicalTrials.gov from the beginning of each database through 26 September 2025. They pooled risk ratios with 95 percent confidence intervals using a random-effects approach, and they also ran subgroup checks.

Crucially, the endpoint wasn’t “blood pressure” as a number. What they pooled were treatment-emergent adverse events that the original trials logged as hypertension-related or hypotension-related. That choice shapes how everything below is interpreted, and it matters again later.

The group is based at the Affiliated Hospital of Southwest Medical University in Luzhou, Sichuan. They report no competing interests.

What tirzepatide showed

Two results, pulling in opposite directions.

For hypertension-related events, the pooled risk ratio is 0.40, with a 95 percent confidence interval from 0.26 to 0.60, p less than 0.001. Put simply, people assigned to tirzepatide in these trials had fewer adverse events that investigators classified as hypertension-related, and the confidence interval sits well away from 1.

For hypotension-related events, the pattern flips. The reported risk ratio is 2.45, confidence interval 1.35 to 4.45, p equal to 0.003. In subgroup work, the increase is stronger at higher doses, risk ratio 2.58, interval 1.38 to 4.81, p equal to 0.003.

The authors frame the first finding as a potent antihypertensive effect and treat the second as something that comes with it rather than as an independent signal. Their bottom line is that tirzepatide lowers hypertension-related adverse events but raises dose-dependent hypotension risk in patients with type 2 diabetes or obesity.

What semaglutide showed

Not much, and that near-neutrality is the point.

They report no statistically significant association for hypertension-related events, risk ratio 0.81, interval 0.57 to 1.15, p equal to 0.233. They also find no significant association for hypotension-related events, risk ratio 1.39, interval 0.81 to 2.36, p equal to 0.232. In both cases the confidence intervals cross 1.

Their description of semaglutide is cautious: a relatively neutral blood pressure related safety profile, while noting that possible protective signals appeared in higher-dose subgroups. They keep that wording soft, and it is better left that way than inflated into a stronger claim.

How to interpret something like this

Three points are worth keeping in view, and none are in conflict with what the authors say.

Adverse events are not the same as measurements

The outcomes here are whatever trial staff recorded and coded, not a standardised series of blood pressure readings. Whether a hypotension event gets captured depends on thresholds for reporting, on how a specific study defined the event, and on what participants brought up. A pooled risk ratio from this kind of material tells you about recorded events, which tracks physiology but does not perfectly mirror it.

For measured values, the closer reference is the SURMOUNT-1 ambulatory blood pressure monitoring substudy published in Hypertension in 2024, which used 24-hour ambulatory measurements rather than adverse-event tallies.

Tirzepatide and semaglutide were not tested against each other

This meta-analysis aggregates trials of each drug against its own comparators, it is not a direct tirzepatide-versus-semaglutide trial. The contrast is therefore a contrast between two collections of studies, with their own populations, comparators, and follow-up lengths. That can point to a hypothesis, but it is a thin foundation for closing the case.

The abstract leaves out details that matter

Heterogeneity metrics, the exact makeup of the dose subgroups, and the weighting of individual trials are not in the abstract. Anyone who wants to lean on the dose-dependence result, arguably the piece with the clearest practical implications, will need the full paper.

Why the pairing makes sense

Once you phrase it carefully, the two signals aren’t contradictory. If a drug shifts blood pressure downward in a population that includes people already taking antihypertensives, more episodes at the low end are what you would expect. That is what happens when an entire distribution moves.

What this analysis contributes is a sense of scale on each side of that shift, plus the suggestion that dose matters. It also puts tirzepatide and semaglutide at different points along the same continuum, which aligns with the broader picture in a 2026 state-of-the-art review that treats incretin analogues as cardiovascular agents.

We recently covered another tirzepatide paper, one that counted how many participants hit multiple targets at once. The methodological lesson carries over: what a composite endpoint does and does not show depends entirely on the counting rules behind it.

What this means for laboratory work

In a research context, the key takeaway isn’t a clinical recommendation. It is that pooled trial data now describe haemodynamic profiles for tirzepatide and semaglutide, and those profiles differ, which matters for any protocol that touches cardiovascular parameters.

It also reinforces a practical point: these compounds shouldn’t be treated as interchangeable stand-ins. They differ in receptor activity, with tirzepatide acting at both GIP and GLP-1 receptors, and this analysis suggests that difference shows up in outcomes beyond weight and glycaemia.

Our tirzepatide reference material and the European research buyer guide cover identity, purity, and documentation for laboratories sourcing the compound.

References

• Chen QX, Zhou XY, Wu Q, et al. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis. Endocrine, 15 August 2026. doi 10.1007/s12020-026-04757-7
• de Lemos JA, Linetzky B, le Roux CW, et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index 27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension, April 2024
• Incretin analogues as cardiovascular agents: a state-of-the-art review. Frontiers in Endocrinology, 2026

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.